Radioimmune Localization of Occult Carcinoma

Rosemary B. Duda*, A. Michael Zimmer, Steven T. Rosen, Katherine A. Gilyon, Denise Webber, Stewart Spies, William Spies, Bruce Merchant

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Patients with a rising serum carcinoembryonic antigen level and no clinical or roentgenographic evidence of recurrent or metastatic cancer present a treatment dilemma. Eleven such patients, 10 with a previously treated colorectal carcinoma and 1 with a previously treated breast carcinoma, received an injection of the anticarcinoembryonic antigen monoclonal antibody ZCE-025 labeled with the radioisotope indium 111. Nuclear scintigraphy was performed on days 3 and 5 through 7 to detect potential sites of tumor recurrence. The monoclonal antibody scan accurately predicted the presence or absence of occult malignancy in 7 (64%) patients. Second-look laparotomy confirmed the monoclonal antibody scan results in the patients with colorectal cancer, and magnetic resonance imaging confirmed metastatic breast cancer. This study demonstrates that In-ZCE-025 can localize occult carcinoma and may assist the surgeon in facilitating the operative exploration. In-ZCE-025 assisted in the initiation of adjuvant therapy for the patient with breast cancer.

Original languageEnglish (US)
Pages (from-to)866-870
Number of pages5
JournalArchives of Surgery
Volume125
Issue number7
DOIs
StatePublished - Jul 1990

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Radioimmune Localization of Occult Carcinoma'. Together they form a unique fingerprint.

Cite this